PCORI Funding Announcement: Assessment of Prevention, Diagnosis, and Treatment Options

| Health Policy and Management Funding




Patient-Centered Outcomes Research Institute (PCORI)


Upper  $2,000,000 USD

Funds available under this RFA total $32 million. The maximum budget for this PFA is $2 million total direct costs. The maximum research period of performance is three years (not including peer review). The maximumbudget includes all research and peer-review-related costs. PCORI will not cover costs for interventions that are being compared in the proposed study. This program does not consider exceptions to the budget and period-of-performance limits. Any application that exceeds the $2 million total direct cost cap or the three-year period of research performance will not be reviewed.


PCORI is seeking applications designed to provide information to inform critical decisions that face patients and caregivers, clinicians, policy makers, and healthcare system leaders. These decisions must beconsequential and occurring now in the absence of sound evidence about the comparative effectiveness of alternative approaches. There must be substantial potential for patients and caregivers to benefit from the newknowledge in ways that are important to them. The premise of this research is that the new knowledge will inform critical choices of patients and stakeholders in health care. This knowledge will provide insight about the comparative benefits and harms of the options and provide information about outcomes that are important to patients.

Research of Interest: Comparative Clinical Effectiveness

Patients, caregivers, and clinicians often lack the appropriate evidence required to make the best choices regarding prevention, screening, diagnosis, monitoring, or treatment. Where therapies or technologies have been approved and marketed, there are often gaps in research comparing their effectiveness with that of other clinical options, and prior research may not have included outcomes that are important to patients and their caregivers. In addition, the existing evidence base may not be relevant for certain patient populations, such as those at the extremes of age or with multiple comorbid conditions.

For this particular PFA on the Assessment of Prevention, Diagnosis, and Treatment Options, PCORI seeks to fund investigator-initiated research that:
– Compares the effectiveness of two or more strategies for prevention, treatment, screening, diagnosis, or management that are known to be efficacious but have not been adequately compared in previous studies; interventions without sufficient evidence of efficacy will be considered only when they are in reasonably common use. PCORI is particularly interested in studies that are conducted in typical clinical populations and that address the full range of relevant patient-centered outcomes (PCOs)
– Addresses a high-priority evidence gap, as identified by prior systematic reviews, clearly defined gaps in clinical guidelines, or other credible evidence reviews
– Investigates, among compared groups, factors that account for variation in treatment outcomes, with attention paid to demographic, biological, clinical, social, economic, or geographic factors, comorbidities, and other factors that may influence those outcomes; strategies may focus on patient populations with a single condition or involve patients with a range of conditions

For this PCORI Funding Announcement (PFA), proposed projects should address the comparison of specific clinical services or strategies that are clearly defined and can be replicated in other clinical settings with minimal adaptations or changes. PCORI does not encourage projects that have the primary goal of developing and testing decision aids or testing the use of lay personnel who perform ancillary services in healthcare settings.

This funding opportunity is broad-based and is not confined to specific clinicalservices or patient populations. However, the program’s goal is to expand the evidence base that pertains to clinical services that would be chosen by clinicians, patients, and caregivers in usual clinical delivery settings. Theservices of interest include:
– Prescription drugs and biologics
– Surgical and other interventional procedures
– Techniques for disease screening
– Vaccinations and other interventions to prevent diseases
– Counseling and behavioral interventions
– Complementary and integrative services
– Rehabilitative services
– Diagnostic tests and procedures

Additional Information:
Cycle 3 2016

Upcoming Deadlines

14 Sep 2016 (Anticipated) – Letter of Intent (Sponsor deadline – required) Cycle 3 2016 opens August 15, 2016.

19 Dec 2016 (Anticipated) – Application (Sponsor deadline – required)

For more information visit